Top Markets
Coin of the day
Becton, Dickinson and Company Becton, Dickinson and Company

Becton, Dickinson and Company

BDX
Rangering i aksjer #389
Becton, Dickinson and Company develops, manufactures, and sells medical... Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Aksjekurs
$154.51
Markedsverdi
$55.98B
Endring (1 dag)
-1.82%
Endring (1 år)
-32.08%
Land
US
Handel Becton, Dickinson and Company (BDX)

Kategori

P/E-forhold for Becton, Dickinson and Company (BDX)
P/E-forhold per March 2026 TTM: 25.86
Ifølge Becton, Dickinson and Company sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 25.86. Ved slutten av 2024 hadde selskapet en P/E på 40.97.
P/E-forholdshistorikk for Becton, Dickinson and Company fra 2000 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) 25.86 -19.12%
2025 31.97 -21.98%
2024 40.97 -17.84%
2023 49.87 39.71%
2022 35.70 7.72%
2021 33.14 -54.23%
2020 72.41 34.11%
2019 53.99 -74.78%
2018 214.12 463.11%
2017 38.02 -0.43%
2016 38.19 1.32%
2015 37.69 108.24%
2014 18.10 22.98%
2013 14.72 8.89%
2012 13.52 8.66%
2011 12.44 -3.18%
2010 12.85 -3.24%
2009 13.28 -21.73%
2008 16.96 -23.68%
2007 22.23 -1.92%
2006 22.66 27.31%
2005 17.80 -34.36%
2004 27.12 65.54%
2003 16.38 10.04%
2002 14.89 -35.06%
2001 22.93 38.04%
2000 16.61 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
58.67 126.92%
US
93.42 261.31%
DE
37.54 45.20%
JP
38.60 49.31%
CH
22.76 -11.99%
US
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.